Abcam to participate in the Morgan Stanley 20th Annual Global Healthcare Conference

1 September 2022, Cambridge, UK – Abcam plc (Nasdaq: ABCM; AIM: ABC) (“Abcam” or the “Company”), a global leader in the supply of life science research tools, announced that Alan Hirzel, Chief Executive Officer, will be participating in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare conference at the Sheraton, New York Hotel in New York at approximately 4.10 p.m. BST (11.10 a.m. EDT) on 14 September 2022.

To access the webcast, please use the following link:

The live audio webcast will also be available in the investor section of Abcam’s corporate website at  An archive will be available after the call at that same address.

For further information please contact:

Abcam +1 617 577 4205
Tommy Thomas, CPA, Vice President, Investor Relations
Numis – Nominated Advisor & Joint Corporate Broker + 44 (0) 20 7260 1000
Freddie Barnfield / Duncan Monteith
Morgan Stanley – Joint Corporate Broker + 44 (0) 207 425 8000
Tom Perry / Luka Kezic
FTI Consulting + 44 (0) 20 3727 1000
Ben Atwell / Julia Bradshaw

About Abcam plc

As an innovator in reagents and tools, Abcam’s purpose is to serve life science researchers globally to achieve their mission, faster. Providing the research and clinical communities with tools and scientific support, the Company offers highly validated antibodies, assays and other research tools to address important targets in critical biological pathways.

Already a pioneer in data sharing and ecommerce in the life sciences, Abcam’s ambition is to be the most influential company in life sciences by helping advance global understanding of biology and causes of disease, which, in turn, will drive new treatments and improved health.

Abcam’s worldwide customer base of approximately 750,000 life science researchers uses Abcam’s antibodies, reagents, biomarkers and assays. By actively listening to and collaborating with these researchers, the Company continuously advances its portfolio to address their needs. A transparent programme of customer reviews and datasheets, combined with an industry-leading validation initiative, gives researchers increased confidence in their results.

Founded in 1998 and headquartered in Cambridge, UK, the Company has served customers in more than 130 countries. Abcam’s ordinary shares are listed on the London Stock Exchange (AIM: ABC) and its American Depositary Shares (ADSs) trade on the Nasdaq Global Market (Nasdaq: ABCM).

For more information, please visit or